Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Commercial and Pipeline Insight - Opioids - Short acting and anti-abuse technologies set to fragment and grow the market (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 26/03/2008
- Report Title: Commercial and Pipeline Insight - Opioids - Short acting and anti-abuse technologies set to fragment and grow the market
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 233
Introduction
The opioid market is currently valued at $7.7 billion and is set to increase over the next 10 years at a CAGR of 2.4%. Despite this market being exclusively comprised of old genericized molecules, novel formulations and delivery methods have stimulated growth over the last 5 years. This growth is set to continue as current market players instigate lifecycle management strategies to retain value.
Scope
Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs. Analysis of patient potential, unmet needs and clinical trial design in the opioid market. Overview of key marketed brands, late- and early-stage pipeline drugs. Identification of future market events that are expected to affect opioid revenues.
Highlights
Short-acting opioids represent good in-licensing opportunities for companies with large sales and marketing resources. This market is expected to triple in value over the next 10 years, driven by Cephalon's Fentora for use in breakthrough pain, and supported by other new short-acting fentanyl formulations.
The long-acting opioid market was valued at over $3 billion in 2007, and is due to grow until the patent expiry of market leader OxyContin in 2011. After a short lived decline, market growth will be stimulated by the launch of anti-abuse formulations, a technical development anticipated to create a $1 billion market.
The topical market represents an opportunity for companies to enter a comparatively underserved market. Although Johnson and Johnson's market leading Duragesic (fentanyl patch) has faced generic opposition since 2005, sales remain relatively strong due to brand strength and the lack of branded competition.
Reasons to Purchase
Benchmark key late-stage pipeline opioids against current market leading brands. Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands. Understand unmet needs and opportunities in the opioid market based on key opinion leader comments.
Scope
Highlights
Reasons to Purchase
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
